中国生物制药今日盘中股价大幅上扬，涨幅达到5.06%，表现显著强于市场。
消息面上，公司近期利好频传。首先，其附属公司北京潮药业的盐酸罗哌卡因缓释溶液新药上市申请已获得国家药监局受理，该药物用于成人术后长效镇痛，为公司产品管线注入新的增长动力。其次，国家医保局近期公示了通过基本医保目录及商保创新药目录调整初步形式审查的药品名单，并首次引入预申报机制，政策层面持续向创新药倾斜，为公司相关创新产品的市场准入与商业保险覆盖打开了增量空间。此外，公司此前宣布拟动用不超过20亿港元进行股份回购，此举彰显了管理层对公司未来发展前景与内在价值的坚定信心。
综合来看，新药研发进展、有利的行业政策环境以及公司积极的资本运作共同构成了此次股价上涨的核心驱动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.